Engineered immune cells take aim at deadly brain tumors

NCT ID NCT05627323

Terminated Disease control Sponsor: Chimeric Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new treatment called CHM-1101 for people with a type of brain cancer (glioblastoma) that has come back or is getting worse. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack tumor cells. The study will enroll 42 adults to find the safest dose and see if the therapy can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CHM-1101 CAR T-cells (immune cells engineered to target brain tumor cells)
What this could lead to: If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is an early Phase 1b trial with only 42 participants, focused mainly on safety and dosing. It may not show strong effectiveness, and CAR T-cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain glioblastoma glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME OF BRAIN

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
St. David's South Austin Medical Center - Sarah Cannon - Austin

Austin, Texas, 78704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.